Skip to main content
Journal cover image

Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.

Publication ,  Journal Article
Wolka, AM; Fairchild, AO; Reed, SD; Anglin, G; Johnson, FR; Siegel, M; Noel, R
Published in: Ther Innov Regul Sci
July 2018

BACKGROUND: Formal incorporation of patients' perspectives is becoming increasingly important in medical product development and decision making. This article shares practical advice regarding how patient advocacy organizations, the pharmaceutical industry, and academic experts in stated-preference research can effectively partner on benefit-risk patient preference studies. METHODS: The authors partnered on a benefit-risk patient preference study related to the treatment of psoriasis. The authors from Duke Clinical Research Institute also share their experiences in collaborating with numerous other organizations in conducting benefit-risk patient preference studies. RESULTS: Upon initiation of the study partnership with appropriate experts, training is important to ensure all collaborators have a common understanding of the methodology, what objectives stated-preference methods can support, and expectations for the project. To the extent possible, partners should align on and document relevant clinical and logistical details prior to study implementation. During study implementation, partners should use good communication practices and document and maintain a record of any changes to the original plan. Presentation of the study results should be tailored to the particular audience, with the appropriate partner leading the presentation based on its format and audience. CONCLUSION: Partners from patient advocacy organizations, the pharmaceutical industry, and academia can effectively collaborate on benefit-risk patient preference studies with sufficient planning and ongoing communication. This article is a call for action for other organizations to engage in sharing of experiences regarding effective partnering in quantifying patient preferences in medical product development.

Duke Scholars

Published In

Ther Innov Regul Sci

DOI

EISSN

2168-4804

Publication Date

July 2018

Volume

52

Issue

4

Start / End Page

507 / 513

Location

Switzerland

Related Subject Headings

  • Statistics & Probability
  • Risk Assessment
  • Research Personnel
  • Patient Preference
  • Patient Advocacy
  • Intersectoral Collaboration
  • Humans
  • Drug Industry
  • Clinical Decision-Making
  • 4905 Statistics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wolka, A. M., Fairchild, A. O., Reed, S. D., Anglin, G., Johnson, F. R., Siegel, M., & Noel, R. (2018). Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers. Ther Innov Regul Sci, 52(4), 507–513. https://doi.org/10.1177/2168479017746404
Wolka, Anne M., Angelyn O. Fairchild, Shelby D. Reed, Greg Anglin, F Reed Johnson, Michael Siegel, and Rebecca Noel. “Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.Ther Innov Regul Sci 52, no. 4 (July 2018): 507–13. https://doi.org/10.1177/2168479017746404.
Journal cover image

Published In

Ther Innov Regul Sci

DOI

EISSN

2168-4804

Publication Date

July 2018

Volume

52

Issue

4

Start / End Page

507 / 513

Location

Switzerland

Related Subject Headings

  • Statistics & Probability
  • Risk Assessment
  • Research Personnel
  • Patient Preference
  • Patient Advocacy
  • Intersectoral Collaboration
  • Humans
  • Drug Industry
  • Clinical Decision-Making
  • 4905 Statistics